Glucosamine
Revu par Dr Krishna Vakharia, MRCGPDernière mise à jour par Dr Colin Tidy, MRCGPDernière mise à jour 20 juil. 2023
Respecte les directives éditoriales
- TéléchargerTélécharger
- Partager
- Language
- Discussion
- Version audio
- Ajouter aux sources préférées sur Google
Professionnels de la santé
Les articles de référence professionnelle sont conçus pour être utilisés par les professionnels de la santé. Ils sont rédigés par des médecins britanniques et basés sur des preuves de recherche, des directives britanniques et européennes. Vous pouvez trouver l'un de nos articles de santé plus utile.
What is glucosamine?
Glucosamine is a natural substance found in mucopolysaccharides, mucoproteins, and chitin.1
Glucosamine has attained great popularity as a nutritional supplement, primarily for osteoarthritis. There have been large industry-sponsored clinical trials as well as independent studies. Glucosamine is popular with patients, in part due to the encouragement of the medical profession who, when it was first marketed, advocated it as a low-risk alternative to non-steroidal anti-inflammatory drugs.2
Mechanism of action
Glucosamine occurs naturally (made by combination of glucose and the amino acid glutamine by the enzyme glucosamine synthetase) and is one of the 'building blocks' of cartilage. Glycosaminoglycans and proteoglycans are larger molecules made from glucosamine in combination with proteins such as collagen and elastin. They form the extracellular matrix and the cartilage in joints.
Animal models and in vitro experiments suggest that glucosamine stimulates cartilage production and inhibits degradation by influencing chondrocyte activity. However, limited in vivo studies suggest that very little orally ingested glucosamine reaches the joint. This does not rule out an unknown mechanism of action elsewhere but leaves no clear theory to explain an effect.3 4
Preuves
Evidence is mixed, with most authors now agreeing that the case for any significant effect is unproven.
A Cochrane review in 2005 found mixed results but did not find evidence that glucosamine was superior to placebo for treating pain and functional impairment. suggested that whilst glucosamine appeared superior to placebo for treatment of pain and functional impairment from symptomatic osteoarthritis in around 2,500 patients, the benefit at three months was less than that measured at six weeks.5
A 2009 systematic review looked at five systematic reviews and one clinical guideline. It concluded that there was evidence for clinical impact but that more research was needed and that as none of the trial data came from the UK, caution should be exercised in applying it here.6
A 2012 review concluded that evidence was at best mixed and that any symptomatic effect observed varied greatly with the preparation used and the quality of the trial.4
A further systematic review in 2103 concluded that glucosamine was ineffective for pain reduction in patients with knee OA, but may have function-modifying effects when administered for more than 6 months. However, glucosamine showed no pain-reduction benefits after 6 months of therapy.7
A 2018 review of 61 randomised controlled trials found that oral celecoxib is more effective than placebo on relieving pain and improving physical function, followed by the combination of glucosamine and chondroitin. Paracetamol was considered likely to be the least effective intervention option for knee and/or hip osteoarthritis.8
Indications
The BNF states that glucosamine can be used for symptomatic relief of mild to moderate osteoarthritis of the knee.1
However, NICE guidance recommends that glucosamine is not offered as a treatment option for osteoarthritis.9
Effets secondaires
The side effects listed in the BNF are:1
Common or very common: constipation; diarrhoea; fatigue; gastrointestinal discomfort; headache; nausea.
Uncommon: flushing; skin reactions.
Rare or very rare: jaundice.
Frequency not known: angioedema; asthma; diabetes mellitus; dizziness; hypercholesterolaemia; oedema; vomiting.
Contre-indications1
The BNF does not provide any contraindications for glucosamine but the cautions list is as follows: asthma; impaired glucose tolerance; predisposition to cardiovascular disease.
The manufacturers advise avoiding during pregnancy and breastfeeding.
Dr Mary Lowth is an author or the original author of this leaflet.
Mises à jour exclusives pour les professionnels de la santé
Restez informé des dernières mises à jour cliniques, des perspectives professionnelles et des conseils fondés sur des preuves. La newsletter Patient Pro sélectionne des contenus essentiels pour les professionnels de santé—livrés directement dans votre boîte de réception.
En vous abonnant, vous acceptez notre Politique de confidentialité. Vous pouvez vous désabonner à tout moment. Nous ne vendons jamais vos données.
Lectures complémentaires et références
- Stuber K, Sajko S, Kristmanson K; Efficacy of glucosamine, chondroitin, and methylsulfonylmethane for spinal degenerative joint disease and degenerative disc disease: a systematic review. J Can Chiropr Assoc. 2011 Mar;55(1):47-55.
- Henrotin Y, Mobasheri A, Marty M; Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis? Arthritis Res Ther. 2012 Jan 30;14(1):201. doi: 10.1186/ar3657.
- Dahmer S, Schiller RM; Glucosamine. Am Fam Physician. 2008 Aug 15;78(4):471-6.
- Formulaire National Britannique (BNF); Services de Preuves NICE (accès réservé au Royaume-Uni)
- Miller KL, Clegg DO; Glucosamine and chondroitin sulfate. Rheum Dis Clin North Am. 2011 Feb;37(1):103-18. Epub 2010 Dec 4.
- Towheed TE, Anastassiades T; Glucosamine therapy for osteoarthritis: an update. J Rheumatol. 2007 Sep;34(9):1787-90.
- Henrotin Y, Mobasheri A, Marty M; Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis? Arthritis Res Ther. 2012 Jan 30;14(1):201. doi: 10.1186/ar3657.
- Towheed TE, Maxwell L, Anastassiades TP, et al; Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD002946.
- Black C, Clar C, Henderson R, et al; The clinical effectiveness of glucosamine and chondroitin supplements in slowing or arresting progression of osteoarthritis of the knee: a systematic review and economic evaluation. Health Technol Assess. 2009 Nov;13(52):1-148. doi: 10.3310/hta13520.
- Wu D, Huang Y, Gu Y, et al; Efficacies of different preparations of glucosamine for the treatment of osteoarthritis: a meta-analysis of randomised, double-blind, placebo-controlled trials. Int J Clin Pract. 2013 Jun;67(6):585-94. doi: 10.1111/ijcp.12115.
- Zhu X, Wu D, Sang L, et al; Comparative effectiveness of glucosamine, chondroitin, acetaminophen or celecoxib for the treatment of knee and/or hip osteoarthritis: a network meta-analysis. Clin Exp Rheumatol. 2018 Jul-Aug;36(4):595-602. Epub 2018 Jan 31.
- Arthrose chez les plus de 16 ans : diagnostic et prise en charge; Directive NICE (octobre 2022)
À propos de l'auteurVoir la biographie complète

Dr Colin Tidy, MRCGP
Médecin généraliste, Auteur médical
MBBS, MRCGP, MRCP (Paediatrics), DCH
Le Dr Colin Tidy est un médecin du NHS, basé dans l'Oxfordshire.
À propos du critiqueVoir la biographie complète

Dr Krishna Vakharia, MRCGP
Médecin-chef pour la santé, Optum UK
MBChB, MRCGP(2013), BMedSci (hons), DFSRH, DRCOG, PGDipDerm (Distn)
Le Dr Krishna Vakharia est un médecin généraliste du NHS. Elle est également examinatrice régulière pour le diplôme de troisième cycle en dermatologie pratique à l'Université de Cardiff, ainsi que médecin-chef pour la santé chez Optum UK.
Historique de l'article
Les informations sur cette page sont rédigées et examinées par des cliniciens qualifiés.
Article également disponible en Anglais, Allemand, Espagnol, Français, Italien, Portugais, Hindi, Hébreu, Arabe, and Suédois.
Prochaine révision prévue : 18 juil. 2028
20 juil. 2023 | Dernière version

Demandez, partagez, connectez-vous.
Parcourez les discussions, posez des questions et partagez vos expériences sur des centaines de sujets de santé.

Vous ne vous sentez pas bien ?
Évaluez vos symptômes en ligne gratuitement
Plus en thérapie médicamenteuse
- Préparations oculaires anti-inflammatoires
- Facteur de nécrose tumorale alpha
- Médicaments antifibrinolytiques et hémostatiques
- Antihistaminiques
- Préparations oculaires antimicrobiennes
- Aides à la décision
- Médicaments dans le sport
- Alimentation entérale et nutrition entérale
- Anesthésie générale
- Vaccination Hib
- THS - consultation initiale
- Soutien nutritionnel en soins primaires
- Anesthésiques locaux oculaires
- Nutrition parentérale
- Analgésie pré-hospitalière
- Précautions pour les patients diabétiques subissant une chirurgie
- Prescrire pour le patient âgé
- Problèmes de prescription et concordance
- Inhibiteurs sélectifs de la recapture de la sérotonine
- Syndrome sérotoninergique